Invitae Corporation Stock Intrinsic Value – INVITAE CORPORATION Reports Q2 Earnings for FY2023 on June 30, 2023

August 26, 2023

🌥️Earnings Overview

INVITAE CORPORATION ($NYSE:NVTA) reported its FY2023 Q2 earnings results for the period ending August 8, 2023 on June 30, 2023. Total revenue was USD 120.5 million, a decrease of 11.8% year-over-year, and net income was USD -206.5 million, a decrease from -2523.5 million the previous year.

Price History

The stock opened at $1.2 and closed at $1.2, indicating an increase of 2.6% from the prior closing price of $1.2. This was in line with the market expectations as analysts had predicted that the stock would increase in value after the release of the financial report. This was driven by strong performance from its core businesses and effective cost management.

This was primarily driven by improved operating efficiency and strong cash flow management. Overall, the performance of INVITAE CORPORATION boded well for investors as it reported strong growth in revenue and earnings per share along with impressive cash flow and debt reduction. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Invitae Corporation. More…

    Total Revenues Net Income Net Margin
    493.88 -799.67 -115.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Invitae Corporation. More…

    Operations Investing Financing
    -300.03 355.63 -135.98
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Invitae Corporation. More…

    Total Assets Total Liabilities Book Value Per Share
    1.52k 1.72k -0.77
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Invitae Corporation are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    28.4% -154.2%
    FCF Margin ROE ROA
    -64.6% 401.0% -31.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – Invitae Corporation Stock Intrinsic Value

    At GoodWhale we have conducted an analysis of INVITAE CORPORATION‘s fundamentals. Our proprietary Valuation Line has determined that the intrinsic value of INVITAE CORPORATION share is around $17.9. Comparing this to its current trading price of $1.2, we can see that the stock is currently undervalued by a huge margin of 93.3%. This suggests that now is a great time to invest in INVITAE CORPORATION stock. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company offers a wide range of tests for hereditary conditions, cancer, and other disorders. Invitae’s competitors include Shin Nippon Biomedical Laboratories Ltd, Telo Genomics Corp, and LungLife AI Inc.

    – Shin Nippon Biomedical Laboratories Ltd ($TSE:2395)

    Shin Nippon Biomedical Laboratories Ltd (SNBL) is a Japanese pharmaceutical company with a market cap of 111.12B as of 2022. The company’s Return on Equity (ROE) is 27.83%. SNBL is engaged in the research, development, manufacture, and sale of pharmaceuticals and medical devices. The company’s products include prescription drugs, over-the-counter drugs, and medical devices. SNBL’s products are sold in Japan and other countries.

    – Telo Genomics Corp ($TSXV:TELO)

    Telo Genomics is a genomic testing company that provides DNA sequencing and analysis services to customers in the healthcare, pharmaceutical, and biotechnology industries. The company has a market cap of 20.8M and a ROE of -45.21%. Telo Genomics is focused on providing its customers with genomic data that can be used to make better informed decisions about their health and the health of their patients.

    – LungLife AI Inc ($LSE:LLAI)

    LungLife AI Inc is a Canadian company that specializes in developing artificial intelligence (AI) solutions for the early detection and diagnosis of lung cancer. The company’s market cap is 31.6M as of 2022 and its ROE is -24.88%. LungLife AI’s AI technology is designed to improve the accuracy of lung cancer diagnosis by analyzing a patient’s CT scan and providing a report within minutes. The company’s products are currently used by over 1,000 radiologists in Canada, the United States, and Europe.


    Investors in Invitae Corporation may be concerned with the FY2023 Q2 earnings results which showed a 11.8% decrease in revenue year-over-year to USD 120.5 million. Net income also decreased substantially to USD -206.5 million compared to the previous year’s figure of -2523.5 million. This could be due to a number of factors, such as a decrease in demand or the introduction of new competitors. Investors should watch for any changes in the company’s strategy, pricing, and product offering to see if these can help strengthen Invitae Corporation’s financial performance.

    Recent Posts

    Leave a Comment